

New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2009

Collection of Selected Free Papers from
the 9th International Conference on
Alzheimer's and Parkinson's Disease AD/PD

Prague, Czech Republic, March 11-15, 2009

Editors
Abraham Fisher
Israel Hanin

MEDIMOND
INTERNATIONAL PROCEEDINGS

© Copyright 2009
MEDIMOND S.r.l. • Via Maserati 5, 40128 Bologna, Italy

MONDUZZI EDITORE

INTERNATIONAL PROCEEDINGS DIVISION



Tel. +39 0514151111 • Fax +39 051 4151125
www.medimond.com • info@medimond.com

All rights reserved. No part of this publication may be reproduced,
stored in a retrieval system, or transmitted, in any form,
or by any means, electronic, mechanical, photocopying,
recording or otherwise, without the prior permission,
in writing, from the publisher.

Printed in October 2009 by Editografica • Rastignano • Bologna (Italy)

Foreword

This is the fourth book of what is becoming a series of companion pieces to the bi-annual conferences on Alzheimer's and Parkinson's diseases (AD/PD). This book contains 56 papers written by selected authors, who had presented their research at the Ninth International Conference on Alzheimer's and Parkinson's Diseases: Advances, Concepts & New Challenges (AD/PD 2009), that took place on March 11-15, 2009 in captivating Prague, in the Czech Republic. The official proceedings (OP) of the Conference will be published early in 2010 by Karger, as a special issue of the journal *Neurodegenerative Diseases*.

The Prague meeting included over 2,300 scientific participants, and was the venue for several hundred invited talks, general talks, posters, and symposia. It was impossible to include all of the important scientific information presented at the meeting under one cover while, at the same time, meeting publishers' cost and profit considerations. We, the co-organizers, therefore decided to restrict contributions to be published in the OP, to chapters based on ORAL, INVITED presentations at the meeting.

We also agreed that Medimond International Proceedings (Medimond) would publish a complementary book to the OP, based on FREE PAPERS presented at the Congress. This additional publication, to be issued in printed volume and CD Rom format, would expand the scope of available scientific information from the AD/PD 2009 proceedings.

Medimond's policy is to provide rapid publication of conference proceedings. We, therefore, agreed with this publisher's request that we, the editors, would only correct major mistakes or errors in scientific logic and fact. We would not concern ourselves with stylistic differences in expression by authors whose first language is other than English, nor with differences in font type, style, or referencing in these chapters. We have also not been too particular in the choice of chapters included in the book, in order to encourage diversity in the topics presented. Each author is solely responsible for the information provided in his/her chapter. The manuscripts have, nevertheless, received our general overview, with minor editorial changes inserted where necessary, in the interest of maintaining scientific integrity, while at the same time enabling the rapid publication of these findings. We trust that this book (and the accompanying CD), together with the OP, will provide the reader with a broader overview of the scope and richness of the program of the AD/PD 2009 conference.

Thus, in summary, we have agreed to allow Medimond to approach participants in the ADPD conference whom we, as co-organizers, were unable to invite to contribute a paper because of limitations in the size of the OP of the conference. In this manner, other scientists would at least have the opportunity to publish their work in this Medimond publication which, while a private product (hence each contributor to this volume was required to pay a fee for publication), will be associated in name with the ADPD meeting.

The papers have been scrutinized by us for quality before we approved this publication. Moreover, we would like to emphasize, as a disclaimer, that neither the ADPD meeting co-organizers, nor Kenes received any compensation whatsoever from Medimond for this product. This book is entirely a profit generator for Medimond, with the stipulation that we, the co-organizers, must give the product our stamp of approval before it can be published.

A thorough and extensive, peer-reviewed editorial process will be employed in the case of the OP document, which is presently in preparation.

Abraham Fisher, Ph.D.

Israel Hanin, Ph.D.

Index

Anosognosia in Alzheimer disease Cho Hyun, M.D., Kwon Jee-Hyun, M.D., Kim Seon-Young, M.D.	1
P300 response in early DLB and AD patients shows different topographic distribution. Bonanni L., Iorio E., Onofrj M., Tiraboschi P., Anzellotti F., Franciotti R., Manzoli L., Borrelli I., Thomas A.	9
Visual Art Improves Communication and Behaviour of AD Patients Musella O., Carloni A., De Marino L., Di Bartolo E., Gaeta G., Di Maggio P. and Fasanaro AM	15
Prenatal Diesel Exhaust Exposure Causes Neurodegenerative Diseases in Adults Sugamata M., Ihara T., Takeda K.	21
Theory of mind and executive abilities in individuals with Parkinson's disease Costa A., Oliveri M., Torriero S., Peppe A., Martini M., Coletta K., Carlesimo G. A., Caltagirone C.	25
An update on EHT 0202 preclinical and clinical development for Alzheimer's Disease therapy Desire L.	29
Polymorphisms of chemokine and chemokine receptor genes in Alzheimer's and Parkinson's Patients Reale M., GattaV., Di Nicola M., Stuppia L., Palka G., Iarlori C., Thomas A., Onofrj M., Gambi D.	33
Management of severe psychotic symptoms associated with Parkinson disease that needed a treatment in the psychiatric ward. Joki Hideto, MD; Endo Masanao, MD; Tachiyama Tetsuya, MD; Kimura Katsuo, MD; Nomiya Tamaki, MD; Shimamura Megumi, MD; Yamada Hitoshi, MD; Takahashi Tatsuya, MD; and Kuroiwa Yoshiyuki, MD	39
Italian Olfactory Identification Test (IOIT): a new quantitative test for the olfactory function. Results in patients with Parkinson's disease. Maremmanni C., Marini P., Ramat S., Purcaro C., Napolitano A., Vanni P., Serra P., Morano P., Palumbo V., Orsini M., Marconi R., Rossi G., Meco G.	41

Immune studies in peripheral blood of patients with alzheimer's disease Lombardi V.R.M., Etcheverría I., Fernández-Novoa L., Seoane S., Cacabelos R.	47
CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish population Llovo R., Tudoli I., Carril J.C, Fernández-Novoa L., Seoane S. and Cacabelos R.	53
Gender aspects in Mild cognitive Impairment (MCI) to Alzheimer's Disease (AD) conversion. A Romanian epidemiological study. Spiru L., Ioancio I., Nuta C., Turcu I.	59
Aging, Neurodegenerative Disease and β -Secretase Murphy M.P., Ahmed R.R., Webb R.L., Holler C.J., Li F., Beckett T.L., Niedowicz D.M., Studzinski C.M., and Head E.	65
Polygenic risk factors related to neurodegeneration in Alzheimer disease: calculation of a genetic predisposition score (gps) Fernández-Novoa L., Llovo R., Tudoli I., Seoane S. and Cacabelos R.	69
Multiple system atrophy and Alzheimer's disease in association: coincidence or comorbidity? Rusina R., Matěj R.	75
A pilot, comparative epigenomic and metabolomic study in healthy elderly, adult and young people Cucu N., Anton G., Radu LG, Turcu I., Spiru L.	83
The PARS Study: Evaluating pre-motor Parkinson disease Jennings Danna, Siderowf Andrew, Stern Matthew, Marek Kenneth and the PARS Investigators	89
Logistic regression as a useful tool to explain genetic risk of stroke Carril JC., Llovo R., Fernández-Novoa L., Cacabelos R.	93
The effect of combination therapy of dopamine agonists for Parkinson's disease Nakamura Shinichiro, Kitami Makiko, Furukawa Yoshiyuki	99
ACE-R: cross-sectional and longitudinal use for cognitive assessment Larner AJ.	103
Evidence for lipid alterations in lipid rafts from alzheimer's disease human brain Díaz M., Martín V., Fabelo N., Santpere G., Puig B., Marín R., Alonso R., Gómez T., Pérez J.A. and Ferrer I.	109
The effect of glycosaminoglycans (gags) on amyloid formation and aggregate toxicity Vilasi S., Irace G., Sirangelo I.	115
Effects of donepezil in patients with various type of dementia Asano S., Toyoda T., Yonekura I., Shimada S., and Tanishima T.	123

Arguments for the reconsideration of procaine as a potent therapeutic molecule in AD/PD	
Turcu I., Spiru L.	127
Marine natural products as $\alpha\beta$ modulators	
García-Palomero E., Usán P., García P., Delgado E., de Austria C., Sáiz G., Pérez M.A., Sánchez-Quesada J., Dorronsoro I., Castro A. and Medina M.	135
Mixture of ferulic acid and garden angelica extract improves cognitive function in Alzheimer patients	
Nakamura S., Sasaki K., Azekawa T., Itami A., Ito T., Kiyohara T., Kono K., Matsuda S., Mizuno Y., Miyahara S., Origasa H., Endo H., Yanagimachi A., Lee HS	141
Xanomeline binding to and activation of muscarinic receptors.	
Jakubík J., Machová E., El-Fakahany E.E., and Doležal V.	145
TGF- β 1-induced TIAF1 self-association leads to apoptosis	
Lee M.H., Lin S.R., Chang N.S.	149
Protofibrillar amyloid-beta down-regulates brain-derived neuro-trophic factor transcript iv in alzheimer's disease	
Fahnestock M., Peng S., Marchese M., Garzon D., and Mufson E.J.	157
Endothelial damage and platelet activation in Alzheimer's disease patients	
Piazza F., Galimberti G., Conti E., Guerrato I., Isella V., Speranza T., Borroni B., Pogliani E.M., Padovani A. and Ferrarese C.	163
Cholesterol modulates amyloid beta peptide 1-42 channel formation in planar lipid membranes	
Meleleo D., Notarachille G., Gallucci E. and Micelli S.	167
Effect of calcium and cadmium ions on amyloid beta peptide 1-42 channel activity	
Notarachille G., Meleleo D., Gallucci E., Micelli S.	173
Role of nitric oxide in the $\alpha\beta_{25-35}$ toxicity in vivo	
Limón I.D., Díaz A., Mendieta L., Guzmán A., Martínez I., Espinosa B., Zenteno E. and Guevara J.	179
Presenilin 1 mediates cell-cell adhesion in transfected L-fibroblasts	
Schwarzman A., Sarantseva S., Soloviev K., Talalaeva E., and Vitek M.P.	187
Sirtuins as a link between ageing and neurodegeneration	
Marques Oldriska, Oliveira Rita M., Moita Luis Ferreira, and Outeiro Tiago Fleming	191
Neuronal Abnormality Topography and Discrimination of MCI developing AD	
Musha T. and Matsuzaki H.	199
GDNF and IGF-1-induced Astrocytic Metallothionein-1 (MT-1) and -2 (MT-2) Protect Neurotoxicity (1)IGF-1	
Watanabe Toshiaki	205

The homozygous weaver mouse as an animal model of parkinson's disease Martí J., Santa-Cruz MC., Serra R., Molina V. and Hervás JP.	213
Deletion of the gene encoding for the enzyme Methionine sulfoxide reductase A increases the toxicity of A β (1-42) in an in vivo model. Minniti A., Inestrosa N. and Aldunate R.	217
Effects of copper on A β -induced pathological features in <i>Caenorhabditis ele-</i> <i>gans</i> . Minniti A., Rebolledo D., Inestrosa N.	221
Anti- β -amyloid (A β) IgG levels in plasma of healthy people measured with a reliable immunoassay Weber A., Minibeck E., Engelmaier A., Ehrlich H. J., Schwarz H. P.	225
Neuromodulatory actions of beta-amyloid on the DA release Mura E., Preda S., Govoni S., Frattini P., Grilli M., Marchi M.	229
Neurofibrillary pathology in the brainstem of the tau mutant pR5 mouse Schröder H., Götz J., Pilz K., Kuhlage S., de Vos R.A.I., Bauer T., Selzer A., Köhler C.	233
Microfluidic system with integrated magnetic carrier for immunoprecipitation of A β peptides Jankovicova B., Zverinova Z., Mohamadi R., Slovakova M., Hernychova L., Faigle W., Viovy J.-L., Bilkova Z.	239
Overexpression of human amyloid precursor protein causes neurodegeneration and loss of synaptic proteins in transgenic <i>Drosophila</i> Sarantseva S., Bolshakova O., Timoshenko S., Vitek M., and Schwarzman A.	245
The Avian Ciliary Ganglion: A useful model for study of the effects of beta amyloid on neurotransmitter release Mazalan Susan, Hart Elizabeth, & Gray D. Bruce	249
Monitoring of A β fibrillization using an improved fluorimetric method. Karafin A., Palumaa P. and Tõugu V.	255
Alzheimer's β -amyloid deposits induce the c-Abl/p73 signaling in AD mo- dels. Cancino G.I., Alvarez A.R.	261
Modified embryo organ culture model system for preclinical studies of growth factors-induced neural tissue differentiation in mammals Stipić J. and Crnek-Kunstelj V.	267
The changes in the lipid phase of brain cell membranes in mice bearing expe- rimental Alzheimer's-like disease induced with the help of olfactory bulbec- tomy. Burlakova E., Molochkina E., Gerasimov N., Goncharova I., Fatkullina L., Goloschapov A.	273
Effect of Proteasome Inhibition on MPP ⁺ -induced GSTP1 Expression in SH-SY5Y Cells Neves Carvalho A., Marques C., Rodrigues E., Pereira P., Gama M. J.	279

Doxycycline, a 2 nd generation tetracycline, protects neuronal cells against glutamate- but not against 6-OHDA-induced cytotoxicity Viana G. B., Nobre-Jr H. V., Calou I. B., Garcia F. A., Leal L.K. A.M. and Andrade G. M.	289
Developmental changes in calcium channels and D ₁ -like receptors involved in the glutamatergic transmission onto rat basal forebrain cholinergic neurons Momiya T.	299
A β causes memory impairment by disturbing the jak2/stat3 axis in hippocampal neurons. Chiba T., Yamada M., and Aiso S.	307
Dual Roles Of Amyloid-Beta And Secreted Forms Of Amyloid Precursor Protein In Culture Luo J.J., Kusiak J., Wallace M., Wallace W.C.	311
Link between Gangliosides, Sphingolipids and Alzheimer's Disease Grimm M.O.W., Grösgen S. and Hartmann T.	317
Author Index	321